Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This Phase 2a study involving Tenofovir Disoproxil Fumarate (TDF) will provide extended
safety data for high-risk men. Secondarily, the study will assess the feasibility of
conducting the trial and evaluate the preliminary effectiveness of TDF 300 mg as an HIV
prevention method when taken once a day.